Regeneron says early trials promising for Covid-19 treatment

Washington (AFP) – The US biotech firm Regeneron said Tuesday its antibody cocktail against the coronavirus reduced viral load and recovery time in non-hospitalized Covid-19 patients during an early-stage clinical trial.”We are highly encouraged by the robust and consistent nature of these initial data,” said George Yancopoulos, the company’s president and chief scientific officer.”We have begun discussing our findings with regulatory authorities while continuing our ongoing trial,” he added.The results related to the first 275 patients recruited into Regeneron’s Phase 1 trial. The patients we…

Read More

HEDGE accordingly